Burns McClellan is the pioneer of biotech investor and public relations. Since 1988, Burns McClellan has served as a strategic investor and public relations partner to the international life sciences industry. As the nation’s oldest independent life sciences investor relations and communications consultancy, we advise companies who specialize in therapeutics, medical devices and diagnostics. Burns McClellan maintains an unparalleled network of leading members of the financial community, including institutional investors, long-term healthcare focused funds, sell-side analysts, investment bankers, venture capital funds and industry thought leaders.

We bridge the gap between strategic communications and the complexities of product development. Our staff of professionals have diverse backgrounds in science, clinical development, regulatory affairs, equity research and investing, banking, management consulting, and marketing/media and corporate communications, providing a broad perspective to address our clients’ needs. We understand the intricacies associated with therapeutic discovery and clinical development – and how to build a compelling investment case targeted at key constituencies to achieve our clients’ organizational and communications objectives.

We believe in strategy before tactics. We work with clients to develop a comprehensive communications strategy that is highly specific to their corporate and clinical objectives. We believe a thoughtful, cohesive, and proactively-applied strategy is the ultimate key to success. We then leverage our decades of collective tactical experience to execute and achieve the best results for our clients.

We are deeply committed to proactive as well as responsive client service. With a history of collaborating with legal counsel, various regulatory bodies, and patient advocacy and clinicians’ groups, Burns McClellan serves clients across all stages of corporate, clinical and financial development. Our mission is to create broader recognition for our companies in the life sciences industry through strategic programs developed for key constituencies, media and the financial community. We take great pride in partnering with companies who, every day, contribute to advancing healthcare with new therapeutic innovations and discoveries.